Sunday 24 June 2018
Contact US    |    Archive
Reuters
4 months ago

Aimmune s peanut allergy drug meets main goal of key study

Feb 20 (Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

Aimmune

 | 

peanut

 | 

allergy

 | 

drug

 | 

meets

 | 

main

 | 

goal

 | 

key

 | 

study

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
USA